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T cell differentiation into distinct functional effector
and inhibitory subsets is regulated, in part, by the
cytokine environment present at the time of antigen
recognition. Here, we show that hypoxia-inducible
factor 1 (HIF-1), a key metabolic sensor, regulates
the balance between regulatory T cell (Treg) and TH17
differentiation. HIF-1 enhances TH17 development
through direct transcriptional activation of RORgt
and via tertiary complex formation with RORgt and
p300 recruitment to the IL-17 promoter, thereby
regulating TH17 signature genes. Concurrently, HIF-1
attenuates Treg development by binding Foxp3 and
targeting it for proteasomal degradation. Impor-
tantly, this regulation occurs under both normoxic
and hypoxic conditions. Mice with HIF-1a-deficient
T cells are resistant to induction of TH17-dependent
experimental autoimmune encephalitis associated
with diminished TH17 and increased Treg cells. These
findings highlight the importance of metabolic cues
in T cell fate determination and suggest that meta-
bolic modulation could ameliorate certain T cell-
based immune pathologies.
INTRODUCTION
Host defense against microorganisms requires a complex
network of specialized T cell populations that are responsible
for triggering inflammation to eradicate the infection, resolving
the inflammatory phase after elimination of the threat, and
attenuating dysregulated or inappropriate immune responses.772 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.Despite their diverse functions, these T cell subsets largely differ-
entiate from the same pool of precursor naive CD4+ T cells upon
stimulation by antigen in the presence of unique cytokine signals
that are present in the microenvironment (Murphy and Reiner,
2002; Zhu et al., 2010). For instance, TH1 cells are induced by
type 1 interferons and propagated by IL-12; TH2 cells require
IL-4; and TH17 cells are induced by IL-6 and TGF-b and propa-
gated by IL-23 and IL-21. The activity of all of these effector
T cells is attenuated by anti-inflammatory regulatory T cells
(Tregs) that inhibit T cell proliferation and autoimmune responses
(Barnes and Powrie, 2009; Sakaguchi et al., 2008). Tregs can be
induced from naive T cells upon exposure to TGF-b and are
propagated by IL-2 (Chen et al., 2003; Davidson et al., 2007;
Rajewsky and von Boehmer, 2008).
Treg are commonly categorized into thymus-derived natural
Treg (nTreg) and induced Treg (iTreg). Both iTreg and nTreg express
Foxp3 as a core subset-specific transcription factor, which acti-
vates a large bank of genes that mediate the suppressive pheno-
type of Treg and also silences many effector T cell genes (Getnet
et al., 2010; Pan et al., 2009; Sakaguchi et al., 2008). TGF-b has
been shown to maintain peripheral nTreg cells that develop in the
thymus, and its deficiency leads to the development of early
lethal autoimmunity. Moreover, TGF-b induces Foxp3 expres-
sion in peripheral naive T cells, leading to the differentiation of
iTregs, which exhibit a suppressive phenotype similar to that
seen in nTreg cells (Sakaguchi et al., 2008).
TH17 and Treg cells share a common requirement for TGF-b in
their differentiation requirements despite expressing distinct
transcriptional regulators (RORgt versus Foxp3, respectively)
and demonstrating opposing functions (inflammatory versus
anti-inflammatory) (Bettelli et al., 2006; Dong, 2008; Littman
and Rudensky, 2010; Mangan et al., 2006; O’Quinn et al.,
2008; Veldhoen et al., 2006). TH17 cells are important in re-
sponses mounted against extracellular bacterial infections of
the intestine and the airways (Korn et al., 2009). Despite
providing a benefit in these settings, TH17 can play a pathologic
role in the induction of several autoimmune diseases, including
collagen-induced arthritis, experimental autoimmune encepha-
lomyelitis (EAE), inflammatory bowel diseases (Fife et al., 2009;
Weaver et al., 2007; Wu et al., 2009), and inflammation-induced
carcinogenesis (Wu et al., 2009). In these models, Treg-mediated
suppression of TH17 responses often plays a protective role
against pathology associated with the disease (Ahern et al.,
2010).
In addition to TGF-b, initial TH17 priming also requires the
cooperative action of IL-6 signaling. Subsequently, IL-23 and
IL-21 play a key role in the maintenance of TH17 differentiation
by enhancing the transcription of IL-17 and other TH17 signature
cytokines (Korn et al., 2009; Littman and Rudensky, 2010). Inter-
estingly, IL-6, IL-21, and IL-23 all activate Stat3, which is critical
for the effects of these cytokines on TH17 cell differentiation
(Zhou et al., 2008; Harris et al., 2007). Though it is now known
that Stat3 induces RORgt gene expression (Harris et al., 2007;
Yang et al., 2007)—the key transcription factor required for
TH17 development (Ivanov et al., 2006) —the mechanism by
which this is accomplished remains unclear. Interestingly, the
defect in TH17 differentiation seen in the absence of Stat3 can
be only partially rescued by RORgt overexpression (Yang
et al., 2008b). Furthermore, although Stat3 binds most of the
genes that have been shown to promote TH17 cell fate determi-
nation, it also binds to many genes that are involved in T cell
survival and proliferation (Durant et al., 2010). Genes bound by
RORgt, on the other hand, are fairly specific for the TH17 differ-
entiation program. Clearly, additional regulators contribute to
the control of the TH17 transcriptional program.
Interestingly, accumulating evidence suggests that TH17 and
iTreg arise fromacommonprecursor. In response toTGF-b in vitro
as well as in vivo, many T cells coexpress RORgt and Foxp3
(Veldhoen et al., 2006; Yang et al., 2008a). Ultimately, depending
on the interplay between additional environmental cues, such as
the relative amounts of IL-6 and TGF-b, one or the other subset
emerges as the dominant phenotype. High TGF-b levels in the
absence of IL-6 induce Foxp3 and repress IL-23R transcription.
Foxp3 can, in turn, bind to the RORgt protein and antagonize its
ability to bind DNA, thus pushing T cell differentiation away from
the TH17 transcriptional program and toward the Treg lineage. On
the other hand, proinflammatory cytokines, such as IL-6 or IL-21
in the presence of low TGF-b, activate Stat3, which overcomes
Foxp3 inhibition of RORgt transcriptional activity. This leads to
the upregulation of the IL-23R, thus pushing T cell differentiation
toward a TH17 fate (Zhou et al., 2008). Ultimate TH17 differentia-
tion is associated with Foxp3 downregulation and sustained,
unopposed RORgt and Stat3 transcriptional activity, although
the mechanisms underlying Foxp3 suppression during TH17
lineage commitment are not fully understood.
In this study, we explored the role of a key metabolic sensor
and regulator in T cell fate determination. We report that
hypoxia-inducible factor 1 (HIF-1), the transcription factor that
mediates the metabolic switch from oxidative phosphorylation
to aerobic glycolysis in response to hypoxia (Semenza, 2007),
in fact regulates the TH17/Treg balance. Specifically, we have
discovered that HIF-1 promotes TH17 differentiation by directlyinducing RORgt transcription and subsequently collaborates
with RORgt to regulate downstream TH17 genes. In addition,
HIF-1 inhibits Treg differentiation through an active process that
targets Foxp3 protein for degradation. Given the plasticity
between TH17 and Treg programs, our study sheds light on how
this balance is subject to metabolic regulation and suggests
new strategies tomanipulate these cell lineage decisions in order
to treat diseases associated with TH17/Treg imbalance.
RESULTS
HIF-1a Expression Is Upregulated in a Stat3-Dependent
Manner in T Cells under TH17-Skewing Conditions
HIF-1 is a heterodimeric transcription factor consisting of a highly
regulated oxygen-sensitive HIF-1a subunit and a constitutively
present b subunit (termed HIF-1b) (Semenza, 2007). HIF-1a
expression in T cells can be induced both by hypoxic and nonhy-
poxic stimuli, including TCR-triggered and PI3K-mediated path-
ways, that result in mRNA upregulation and protein stabilization
(Lukashev et al., 2006). Intrigued by a potential link between the
requirement for Stat3 in the TH17 program and our previous
observation that HIF-1a is a target gene for activated Stat3 in
tumor cells (Harris et al., 2007; Xu et al., 2005), we tested the
hypothesis that HIF-1a plays a positive role in TH17 develop-
ment. We began by analyzing HIF-1amRNA expression in helper
T cell subsets using qRT-PCR and found that HIF-1amRNA was
most highly expressed in TH17 cells (Figure 1A). When naive
T cells were activated in the presence of TGF-b + IL-6 (TH17-
skewing conditions), HIF-1a mRNA increased, peaked after
48 hr of culture, and then began to decline (Figure 1B) relative
to consistently low background signal established using HIF-1a
knockout (HIF-1a/) T cells (generated by crossing CD4cre 3
HIF-1aflox/flox mice, termed T-HIF-1/ mice). T-HIF-1/ mice
had normal development of CD4+ and CD8+ T cells, B cells,
and dendritic cells (Figure S1 available online). Whereas wild-
type (WT) T cells activated under TH17-skewing conditions
accumulated IL-17A and RORgt transcripts over time, the induc-
tion of these TH17-associatedmRNAs by HIF-1a deficient T cells
was minimal (Figure 1C and 1D). Because HIF-1a mRNA was
upregulated during in vitro TH17 differentiation and RORgt and
IL-17A mRNA induction were significantly diminished in the
absence of HIF-1a, we suspected that HIF-1a regulates im-
portant components of the TH17 pathway. Furthermore, we
measured HIF-1a and HIF-1b protein in T cells stimulated with
differing levels of IL-6 and TGF-b. Whereas HIF-1b expression
was constitutive as expected under all treatments, both TGF-b
and IL-6 alone induced HIF-1a, and the combination of the two
generated significantly higher levels of HIF-1a protein—even
under normoxic conditions (Figure 1E). As Stat3 is known to
mediate TH17 lineage commitment and has previously been
shown to regulate HIF-1a in tumor cell lines, we hypothesized
that HIF-1a induction may be diminished in Stat3-deficient
T cells activated under TH17-generating conditions. Indeed, after
isolating CD4+CD62LhighCD25(naive) Stat3-deficient T cells
from CD4-cre 3 Stat3flox/flox mice and culturing them under
TH17 skewing conditions for 4 days, very little HIF-1a protein
was detected by western blot (Figure 1E). Furthermore, a chro-
matin immunoprecipitation (ChIP) experiment was carried outCell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc. 773
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Figure 1. HIF-1a mRNA Is Upregulated in T Cells under TH17-Skewing Conditions in a Stat3-Dependent Manner
(A) Naive (CD4+CD25CD62Lhigh) T cells were cultured under TH-cell subset-inducing conditions, and HIF-1 mRNA was detected by qRT-PCR.
(B–D) Naive T cells from wild-type (WT, HIF-1a+/+) or CD4Cre 3 HIF-1aflox/flox mice (ko, HIF-1a/) were stimulated in the presence of TGFb and IL-6. RNA was
isolated from these cells, and qRT-PCR was performed at different time points during culture to measure HIF-1a (B), IL-17 (C), and RORgt (D) transcript levels.
(E) WT or Stat3/ (obtained fromCD4Cre3 Stat3flox/floxmice) naive CD4+ T cells were isolated and cultured under the indicated conditions for 2 days, followed by
SDS-PAGE and western blotting using antibodies against HIF-1a (top), HIF-1b (middle), and tubulin (bottom), respectively.
(F) A ChIP assay was used to examine direct Stat3 binding to the HIF-1a promoter.
(A)–(D) and (F) depict the mean + SD of at least three experiments; (E) is a representative result. See also Figure S1.to test whether Stat3 directly induces HIF-1a gene expression in
TH17 cells. Stat3 was directly associated with the promoter
region of HIF-1a in the WT TH17-skewed T cells, but not at the
promoter region of GAPDH (Figure 1F). These findings confirm
that HIF-1a expression is induced in T cells during TH17 differen-
tiation in a Stat3-dependent manner.
HIF-1 Positively Regulates TH17 Development
at Multiple Levels
Further analysis of TH17 differentiation by intracellular staining
was performed on WT and HIF-1a/ T cells. We observed
significant induction of IL-17A protein by WT T cells stimulated
with TGF-b and IL-6 (Figure 2A). Strikingly, the pattern of IL-
17A and Foxp3 protein expression in HIF-1a/ T cells cultured
under the same conditions was dramatically altered (Figure 2A,
right). In agreement with the mRNA results from Figure 1C, these
HIF-1-deficient T cells displayed a marked reduction in IL-17A+
cells. Despite this notable disparity in IL-17 induction, no signif-
icant differences in IFN-g or IL-4 were seen between WT and
HIF-1a/ T cells under TH1- or TH2-skewing conditions (Fig-
ure S2A), and CD4+ cells from both groups showed comparable774 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.proliferative capacity (Figure S2B). These results suggest that
HIF-1a deficiency specifically affects the TH17 pathway, as
opposed to creating a global defect in T cell proliferation or
differentiation capacity.
The mRNA expression of other TH17-related genes such as IL-
17F and IL-23R was also much lower in HIF-1a/ T cells than in
WT T cells, indicating that HIF-1 regulates multiple genes in the
TH17 program (Figure 2B). Furthermore, we also noted a dramatic
increase in theproportionof Foxp3+ cells inHIF-1a/T cells (Fig-
ure 2A). To directly assess the role of HIF-1a in TH17 program-
ming, we used retroviral transduction to overexpress HIF-1a in
naive CD4+ cells followed by detection of IL-17A and IFN-g by
intracellular cytokine staining (ICS). The ectopic expression of
HIF-1a substantially increased the percentage of IL-17A+ cells
even in the absence of the TH17-driving cytokines IL-6 and TGF-b
(Figure 2C). This induction of IL-17A was associated with the up-
regulation of both RORgt mRNA and protein (Figure S2). The
IL-17A+ cell population was also significantly increased upon
overexpression of HIF-1a under TH17-skewing conditions (Fig-
ure 2C, right). These results support the notion that HIF-1amight
facilitate TH17 development through the upregulation of RORgt.
AC
D
B
R
el
at
ive
 m
R
N
A 
ex
pr
es
sio
n
Figure 2. HIF-1a Is Required for TH17 Development In Vitro
(A) Naive T cells isolated from wild-type (WT, HIF-1a+/+) or CD4Cre3HIF-1aflox/flox (HIF-1a/) mice were cultured under TH17-skewing conditions with anti-CD3/
CD28 and TGFb, IL-6, and anti-IFNg, IL-12, and IL-4 antibodies for 6 days. Cells were then stained for IL-17 and Foxp3 (see Experimental Procedures). Numbers
represent the percentage of CD4+ cells positive for the indicated marker.
(B) FACS-sorted naive CD4+ T cells fromWT or T-HIF-1a/micewere activated and cultured under TH17 skewing for 4 days. Total RNAwas isolated, andmRNA
expression of Il17, Il17f, and IL23r genes was assessed by qRT-PCR. For each gene, expression level inHIF-1a/ T cells was set to 1. The mean + SD of at least
three trials is shown.
(C) Naive CD4+ T cells were activated with anti-CD3/CD28 under either neutral (anti-IL-4 and anti-IFNg antibodies) or TH17-skewing conditions and were
transducedwith a bicistronic retrovirus expressing HIF-1a-GFP or GFP alone. Intracellular cytokines were stained and analyzed in GFP+ cells. Numbers represent
the percentage of gated GFP+ cells.
(D) Naive T cells isolated from WT or T-HIF-1a/ mice were activated as described for (A) under normoxia or hypoxia (see Experimental Procedures).
(C) and (D) represent at least two independent experiments. See also Figure S2.The fact that HIF-1a is a major sensor of metabolic cues,
such as oxygen tension, suggests that this protein could be
an important link between metabolism and T cell fate deter-
mination. To formally test this, we asked whether hypoxia,
which stabilizes HIF-1a protein levels and subsequent tran-
scriptional activity, could affect TH17 differentiation. Indeed,
after TH17 skewing, we observed a higher proportion ofIL-17A+ cells in hypoxic compared to normoxic culture condi-
tions. This increase was abrogated in HIF-1a/ T cells (Fig-
ure 2D and Figure S2E), indicating that the hypoxia-induced
enhancement of TH17 differentiation is HIF-1a dependent.
These findings support the idea that metabolic cues modulate
T cell differentiation and that HIF-1 is an important mediator
of this effect.Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc. 775
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Figure 3. HIF-1a Transactivates RORgt Transcription and Is Necessary for RORgt-Driven TH17 Differentiation In Vitro
(A) Jurkat T cells were cotransfected with a luciferase reporter under the control of a wild-type RORgt promoter or one with a mutated HIF-1-binding site. At 24 hr
posttransfection, cells were either treated with PMA and ionomycin or left untreated prior to analysis of luciferase activity, which was normalized to that of Renilla
luciferase.
(B) Jurkat T cells were transfected with a RORgt-luciferase reporter plasmid (incorporating the RORgt promoter) along with plasmid encoding either wild-type
HIF-1a or a HIF-1a mutant (with a DNA-binding domain deletion). At 24 hr posttransfection, cells were stimulated and luciferase activity was assessed as
described in (A).
(C) A ChIP assay was used to measure direct HIF-1 binding to the RORgt promoter. Data are shown for three independent experiments (mean + SD).
(D and E) Naive WT or HIF-1a/ CD4+ T cells were activated with anti-CD3/anti-CD28 under neutral (anti-IL4 and anti-IFNg antibodies) conditions and were
transduced with either a bicistronic retrovirus expressing RORgt-GFP or the GFP containing empty vector. Intracellular IL-17 and Foxp3 were stained. The plots
shown are gated on GFP+ cells. These experiments were repeated at least twice with consistent results.
See also Figure S3.HIF-1a Activates RORgt Transcription and Cooperates
with RORgt and p300 to Activate the IL-17A Gene during
TH17 Development
Next, we sought to further dissect the molecular mechanism by
which HIF-1a regulates TH17 development. Given that RORgt is
a key transcriptional regulator of TH17 cells, as well as the
dramatically blunted induction of RORgt observed in HIF-1a/
T cells (Figure 1D), we determined whether HIF-1a directly regu-
lates RORgt gene expression. We used a reporter assay with the
luciferase gene under the control of the 1.1 kb RORgt promoter
(Figures S3A and S3B). Transfection of Jurkat cells with the
RORgt promoter-driven reporter construct, together with
increasing amounts of HIF-1a-encoding plasmid, indeed caused
corresponding increases in RORgt promoter activity, particularly
upon PMA and ionomycin stimulation (Figure S3C). Analysis of
the RORgt promoter sequence revealed that a hypoxia response
element (HRE, a conserved HIF-1a-binding site) is located in the
proximal region of the RORgt promoter (Figure S3A). To further776 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.assess the importance of HIF-1a in RORgt promoter activation,
we tested the reporter activity of a promoter with mutated HIF-
1a-binding sites (Figure S3B). The mutated constructs had
much lower luciferase activity compared to that of a wild-type
RORgt promoter-driven luciferase reporter (Figure 3A). Likewise,
the expression of a Hif1a mutant gene lacking the DNA-binding
domain failed to activate the wild-type RORgt promoter (Fig-
ure 3B). Because the human and mouse RORgt promoter
sequences share a high degree of identity as well as a conserved
HRE (Figure S3A), we also tested the importance of HIF-1a in
activation of the human RORgt promoter. Luciferase assays
using the human sequence demonstrated that HIF-1a activates
this promoter in a similar fashion to that of the mouse (Figures
S3D and S3E). These results suggest that HIF-1 can regulate
RORgt gene expression.
To further dissect this mechanism, a ChIP assay was em-
ployed to test whether HIF-1a directly binds to the promoter
region of the RORgt gene in primary, in vitro-generated TH17
cells. Indeed, HIF-1awas found to bind to the HRE located at the
RORgt promoter, but not the promoter of the non-HIF-1a-regu-
lated Gmpr gene (Figure 3C and Figures S4A–S4D). These
results collectively indicate that HIF-1a directly transactivates
RORgt gene expression.
Because our results suggested that RORgt acts directly on the
IL-17A promoter, we asked whether RORgt could rescue TH17
development in HIF-1a/ T cells. In HIF-1a+/+ T cells, retroviral
RORgt expression induced a significantly higher proportion of
IL-17A+ cells (45.7%) under nonskewing conditions, compared
to control retrovirus recipients (0.72%) (Figures 3D and 3E,
left). However, ectopic RORgt expression in HIF-1a/ T cells
induced a strikingly diminished population of IL-17A+ cells
(1.33%) (Figure 3E, right). These results suggest that HIF-1a
not only directly mediates RORgt gene expression, but also
is required for the full function of RORgt in IL-17A gene
transcription.
To gain further insight into how HIF-1a and RORgt coregulate
IL-17A transcription, we performed a luciferase reporter assay to
determine whether transient expression of HIF-1a and RORgt
could activate the 1.3 kb IL-17 promoter. The expression of
wild-type HIF-1a in the presence of RORgt resulted in signifi-
cantly increased reporter gene activity over that induced by
RORgt alone (Figure 4A). In striking contrast to our findings
with the RORgt promoter, a HIF-1a mutant with a characterized
DNA-binding domain deletion (Arany et al., 1996) showed no
defect in inducing reporter gene activity, which implies that
DNA binding is dispensable for HIF-1a-mediated IL-17A expres-
sion. Because the DNA-binding domain of HIF-1a did not appear
to be required for its function in facilitating RORgt activity, we
speculated that HIF-1a might physically associate with RORgt,
serving as a coactivator for RORgt without direct DNA binding.
To test this hypothesis, a Flag-tagged HIF-1a plasmid was coex-
pressed with Myc-tagged RORgt in Jurkat T cells. HIF-1a was
found to coimmunoprecipitate (co-IP) with RORgt (Figure S4E).
The association between HIF-1a and RORgt was further con-
firmed by co-IP of endogenous HIF-1a and RORgt in T cells
cultured under TH17-skewing conditions (Figure 4B). To verify
that the interaction between HIF-1a and RORgt was direct, we
employed affinity-purified recombinant GST fusion proteins to
pull downMyc-RORgt from 293T cell lysate. GST-HIF-1a (amino
acids1–80), rather than GST alone, was bound to RORgt (Fig-
ure S4F). Further testing this apparent direct association of
RORgt and HIF-1a, we purified His-tagged RORgt from E. coli,
and a GST pull-down assay was carried out using GST or
GST-HIF-1a fragments as indicated. Only GST fusions of the
HIF-1a N terminus (1–80 aa), but not GST alone or other
HIF-1a fragments, successfully pulled down RORgt (Figure 4C).
Taken together, these results suggested a direct interaction
between the two proteins in vitro.
Because it has been shown that the transcription factor p300
is critical for HIF-1a-mediated gene activation under hypoxic
conditions, we hypothesized that HIF-1a might function in
a complex with RORgt by recruiting p300 to activate target
genes such as IL-17A. To test this hypothesis, a ChIP assay
was employed to determine whether RORgt, HIF-1a, and p300
associate with the IL-17A promoter during TH17 differentiation.
Indeed, we detected localized binding of RORgt, HIF-1a, andp300 to the IL-17A promoter determined using primers flanking
the RORgt-binding site located at the IL-17A promoter region
(Figure 4D). This binding, as analyzed by ChIP, was specific
because no significant signal could be detected at a non-
RORgt-binding region within the IL-17A promoter. Furthermore,
ChIP analysis revealed that HIF-1awas recruited to several other
putative RORgt-binding regions, including CNS2. This recruit-
ment of HIF-1a was dependent on RORgt because it was abro-
gated in T cells from RORgt knockout mice (Figures S5A–S5D).
Additionally, we observed similar colocalized binding of RORgt,
HIF-1a, and p300 at the promoters of the TH17 signature genes
IL-17F and IL-23R (Figure 4E). The role of the RORgt/HIF-1a/
p300 complex in the activation of the IL-17A promoter was
further confirmed by reporter assays in Jurkat and 293T cells.
Surprisingly, coexpression of RORgt, HIF-1a, and p300 led to
a more than 10-fold increase in luciferase activity compared to
that induced by combinations of any two of these proteins
(Figures S5E andS5F). However, aHIF-1amutantwith aC-termi-
nal deletion of the p300-binding domain (Arany et al., 1996) failed
to synergize with RORgt and p300 in the activation of the IL-17A
promoter, implying that p300 is required for the full function of
RORgt and HIF-1a in the regulation of IL-17A gene expression
(Figure S5E). In addition, IL-17A production in Jurkat T cells co-
transfected with plasmids encoding RORgt, HIF-1a, and p300
was further increased under hypoxic conditions (Figure 4F).
These results suggest that, though active under normoxic condi-
tions, HIF-1a’s ability to promote IL-17A production is indeed
modulated by oxygen tension. Of note, the gut, which is known
to be relatively hypoxic under physiologic conditions (Koch,
2002), contains a high proportion of IL-17A-producing cells.
We found that, under steady-state conditions, T-HIF-1/ mice
had reduced proportions of IL-17A+ cells in the lamina propria
(Figures S6A–S6D), indicating a potential role for HIF-1a in pro-
moting TH17 development in the context of microbial influences.
p300 possesses histone acetyltransferase (HAT) activity
(Thompson et al., 2004). In order to determine whether this
HAT activity is required for the RORgt/HIF-1a /p300 complex-
mediated IL-17A gene expression, we performed cotransfection
studies using a p300mutant with a HAT domain deletion (Dp300)
(Youn et al., 2000). Wild-type p300, but not Dp300, could syner-
gistically enhance IL-17A promoter activity in the presence of
HIF-1a and RORgt (Figure S5E). Furthermore, a HIF-1a mutant
with a deletion in its p300-binding domain (Arany et al., 1996)
fails to activate the IL-17A promoter. These findings indicate
that RORgt and HIF-1a, through recruitment of p300 to the
IL-17A promoter, acetylate histones to ‘‘open’’ the chromatin
structure and facilitate gene expression. In support of this notion,
ChIP assays revealed that histones H3 and H4 around the IL-17A
promoter region were highly acetylated in WT compared to
HIF-1a/ T cells under TH17-inducing conditions (Figure 4G).
Similarly, hyperacetylated histones H3 and H4 were associated
with the promoter of TH17 signature genes IL-17F and IL-23R
in WT, but not in HIF-1a/, TH17 cells (Figures S6E and S6F).
Taken together, these results demonstrate that HIF-1 plays
a dual role in regulating IL-17A transcriptional activity by directly
activating RORgt transcription and then associating with RORgt
at the IL-17A promoter to recruit p300, thus generating a permis-
sive chromatin structure.Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc. 777
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Figure 4. RORgt, HIF-1a, and p300 Bind to the IL-17 Promoter to Regulate Its Gene Expression
(A) A HIF-1a mutant (HIF-1a-DDBD, with the DNA-binding domain deleted) retains the capacity to activate IL-17 promoter-driven luciferase activity in the
presence of RORgt. Jurkat T cells were transfected with an IL-17 promoter-driven luciferase reporter along with the indicated plasmids followed by stimulation
and assessment as described for Figure 3A. Data are representative of at least three experiments (mean and SD of triplicate transfections).
(B) The interaction between HIF-1a and RORgt was examined with coimmunoprecipitation. FACS-sorted CD4+ T cells were activated and cultured under TH17-
skewing conditions for 5 days. The whole-cell lysate was immunoprecipitated with either anti-RORgt (left) or anti-HIF-1a antibodies (right), resolved by
SDS-PAGE, and blotted with the indicated antibodies.
(C) RORgt interacts with the N terminus of HIF-1a. His-tagged RORgt purified from E. coliwas incubatedwith different fragments of GST-HIF-1a also purified from
E. coli as indicated, followed by pull-down with GST beads, resolution by SDS-PAGE, and Western blotting with anti-RORgt (top and bottom) antibodies, or
anti-GST (middle).
(D and E) FACS-sorted CD4+ T cells fromWT orHIF-1a/mice were activated under TH17-skewing conditions (as described for B) prior to harvest for ChIP assay
utilizing anti-RORgt, anti-HIF-1a, or anti-p300 antibodies.
(F) Hypoxia enhances the activation of IL-17 promoter-driven luciferase activity by HIF-1, RORgt, and p300. Jurkat T cells were transfected with a IL-17 promoter-
driven luciferase reporter along with the indicated plasmids under normoxia or hypoxia, followed by stimulation and assessment as described for Figure 3B.
(G) Histone hyperacetylation at the IL-17 promoter was detected by ChIP assay in WT and HIF-1a/ T cells under TH17-skewing conditions for 5 days.
(D–G) Mean + SD of at least three independent experiments.
See also Figure S4, Figure S5, Figure S6, and Table S1.HIF-1a Mediates Foxp3 Protein Degradation
during TH17 Development
Although we established a role for HIF-1 in IL-17A gene regula-
tion, it was unclear how HIF-1 deficiency caused Foxp3 protein778 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.accumulation in T cells under in vitro TH17-inducing conditions
(Figure 2A). Curiously, Foxp3 mRNA levels in WT and HIF-1a/
T cells stimulated under TH17-skewing conditions were essen-
tially identical (Figure 5A). This implies that HIF-1 might be
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Figure 5. HIF-1a-Mediated Foxp3 Degradation through Proteasomal Degradation Pathways
(A) Naive T cells from either WT or T-HIF-1a/mice were cultured and stimulated in the presence of TGFb and IL-6, and qRT-PCR was performed to measure
Foxp3 mRNA at different times.
(B) HIF-1a/ T cells displayed enhanced Foxp3 accumulation during in vitro Treg differentiation. Naive T cells from HIF-1a+/+ and T-HIF-1a/ were isolated by
FACS and activated under Treg skewing (5 ng/ml TGFb, 100 U IL-2). Cells were stained for Foxp3 after 72 hr. Shown are representative histograms for HIF-1a+/+
(red line) and HIF-1a/ (blue line) cells from three experiments. An isotype control is shown in green. Numbers represent the mean percentage of Foxp3+ cells.
(C) Foxp3 protein is lost upon culture of WT T cells with IL-6 but remains unchanged inHIF-1a/ Foxp3+ T cells. Naive T cells were activated under Treg-skewing
conditions (TGFb, 5 ng/ml) with the indicated doses of IL-6 for 4 days. Western blotting was used to measure Foxp3 protein level.
(D) Hypoxia reduced expression of Foxp3 by naive T cells during in vitro differentiation. Naive T cells isolated from Foxp3-GFP reporter mice
(CD4+GFPCD62Lhigh) were cultured under Treg-skewing conditions (see B) in either a hypoxic chamber or under normoxia (blue and red lines, respectively).
Numbers represent the mean percentage of CD4+ cells expressing GFP (Foxp3+) from three experiments.
(E) HIF-1a interacts with Foxp3 in iTreg cells. FACS-sorted CD4+ T cells were activated and cultured under iTreg-skewing conditions for 4 days. Cell lysates were
immunoprecipitated with anti-HIF-1a (left) or anti-Foxp3 antibodies (right), followed by SDS-PAGE and western blotting.
(F–H) HIF-1amediates Foxp3 degradation. 293T cells were cotransfected with plasmids encoding Foxp3+/ ubiquitin and increasing amounts of WTHIF-1a (F) or
mutant HIF-1a (p420A and p564A) (G) or a deleted ODD domain (CA5-HIF-1a) (H). CoIP and Western blots were probed as indicated.
(I and J) Naive T cells were cultured under Treg-skewing conditions in normoxia (N) or hypoxia (H) for 4 days. Cells were harvested and lysed, followed by
immunoprecipitation with anti-Foxp3 or control IgG antibodies. The pulled down protein along with an input control were resolved by SDS-PAGE, followed by
western blot. Depicted are typical findings from three independent experiments.
Data shown are representative of at least three independent experiments (mean + SD). See also Figure S7.involved in Foxp3 protein modulation in addition to its role in the
transcriptional activation of the TH17 pathway. Further evidence
supporting this hypothesis comes from analysis of Foxp3 protein
levels in T cells cultured under Treg-skewing conditions (TGF-b
plus IL-2). In concordance with our findings in T cells cultured
under TH17 skewing conditions,HIF-1a
/ T cells cultured under
Treg conditions also expressed substantially more Foxp3 thandid WT T cells (Figure 5B and 5C). These findings suggest that,
under both Treg- and TH17-skewing conditions, HIF-1a downre-
gulates Foxp3 protein levels despite demonstrating no effect on
Foxp3 mRNA levels (Figure 5A). Based on these findings, we
sought to determine whether Foxp3 levels were sensitive to
hypoxia. T cells were thus cultured with TGF-b and IL-2 under
hypoxic conditions. Foxp3+ cells were significantly decreasedCell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc. 779
under these hypoxic conditions relative to normoxia (Figure 5D).
Thus, hypoxic culture conditions have opposite effects on IL-17
and Foxp3 induction. Compatible with this in vitro finding,
steady-state levels of Foxp3+ cells in the lamina propria of the
gut, which, as indicated above (Koch, 2002), is relatively hy-
poxic, are significantly increased in T-HIF-1/ mice (Figures
S6A–S6D).
We next asked whether a physical interaction between Foxp3
and HIF-1a existed. Immunoprecipitation and western blot
analysis of 293 T cells cotransfected with plasmids encoding
HIF-1a and Foxp3, in fact, demonstrated a physical interaction
between these two molecules (Figure S7A). This interaction
between HIF-1a and Foxp3 was further confirmed by endoge-
nous co-IP in iTreg cells (Figure 5E). The HIF-1a-binding domain
was further mapped to the C terminus of Foxp3 (Figure S7B), and
the Foxp3-binding domain in HIF-1a was found to be within the
N-terminal 80 amino acids by GST pull-down experiments (Fig-
ure S7C). Based on these results, we sought to determine
whether HIF-1a could regulate Foxp3 protein levels through
a mechanism completely distinct from its classic role as a tran-
scriptional regulator. In particular, we hypothesized that HIF-1
might target Foxp3 for degradation. Indeed, upon cotransfection
of 293T cells with Foxp3 and increasing amounts of Flag-tagged
HIF-1a, Foxp3 protein levels progressively decreased (Fig-
ure 5F). On the other hand, RORgt protein levels remained un-
changed upon cotransfection with HIF-1a (Figure S7D). It has
been well established that ubiquitin-dependent degradation of
HIF-1a itself occurs via proline hydroxylation at amino acid posi-
tions 402 and 564 by prolyl hydroxylases (PHDs). Hydroxylated
HIF-1a is subsequently bound by the von Hippel-Lindau protein
(VHL), which recruits the Elongin-C-Elongin-B-Cullin-2-E3-
ubiquitin ligase complex, thereby targeting HIF-1a for degrada-
tion by the 26S proteasome (Semenza, 2007). We wondered
whether HIF-1a’s ability to induce Foxp3 protein degradation
was dependent on this very mechanism. To address this, we co-
transfected 293T cells with Foxp3 and a HIF-1amutant in which
prolines 402 (p402A) and 564 (p564A) were mutated to alanines,
making HIF-1a resistant to both hydroxylation by PHDs and sub-
sequent proteasomal degradation. The expression of P402A and
P564A HIF-1a failed to induce Foxp3 degradation (Figures 5G
and 5H). Similar cotransfection assays using a HIF-1a plasmid
containing an oxygen dependent domain (ODD) deletion (CA5-
HIF-1a) further demonstrated that a nonproline hydroxylatable
HIF-1a was incapable of mediating Foxp3 degradation (Figures
5G and 5H). Knockdown of PHD2 with siRNA also eliminated
the ability of wild-type HIF-1a to mediate the degradation of
Foxp3 (Figure S8A). HIF-1a-mediated Foxp3 degradation was
completely inhibited in the presence of a proteasome inhibitor
(Figure S8B). Furthermore, we assessed whether Foxp3 itself
could be ubiquitinated under hypoxic conditions in primary
iTregs. Hypoxic culture significantly enhanced both Foxp3 ubiqui-
tination and degradation in these cells (Figures 5I and 5J). Fur-
thermore, this ubiquitin-mediated Foxp3 degradation process
could be prevented by addition of the proteasomal inhibitor
MG132 to iTreg cells under hypoxia. Collectively, these results
are compatible with a scenario in which HIF-1 mediates
Foxp3 degradation via PHD-VHL-ubiquitin-mediated proteaso-
mal degradation, although future studies are needed to delineate780 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.precisely how HIF-1a protein turnover dynamics in T cells modu-
late Foxp3 levels.
Collectively, these in vitro differentiation studies, alongside our
transcriptional and biochemical analyses, suggest a model in
which HIF-1a is transcriptionally activated via Stat3 signaling in
differentiating T cells, resulting in the enhancement of the TH17
genetic program via a RORgt/p300-dependent mechanism
and repression of the Treg transcriptional program through
induced degradation of Foxp3.
MicewithHIF-1a-Deficient TCells Fail toMount a Strong
TH17 Response, Have Increased Treg Numbers, and Are
Resistant to EAE
Our in vitro findings that HIF-1a regulates the TH17/Treg balance
prompted us to test its role in vivo in the setting of a pathologic
TH17-dependent autoimmune disease. TH17 cells are the major
pathogenic population in experimental autoimmune encephalo-
myelitis (EAE), a mouse model of multiple sclerosis, although
factors besides IL-17A and IL-17F can contribute to the disease.
Immunization of B6 mice with myelin oligodendrocyte glycopro-
tein peptide (MOG35–55) in complete Freund’s adjuvant (CFA)
induces a TH17-dependent response that induces encephalitis.
After a peak of encephalitis, clinically discernible by various
gradable neurologic signs (including tail paralysis, progressing
to hind and front limb paralysis), the disease remits, concomitant
with expansion of Tregs that can silence the TH17 encephalitic
process. Strikingly, WT mice immunized with MOG35–55 devel-
oped EAE, whereas T-HIF-1a/mice were highly resistant (Fig-
ure 6A). At peak disease, lymph node-, spleen-, and central
nervous system (CNS)-infiltrating CD4+ T cells from WT mice
contained higher proportions of IL-17+ cells compared to those
of T-HIF-1a/mice (Figures 6B and 6C). In contrast, T-HIF-1/
mice showed a significant increase in the percentage of CD4+
Foxp3+ cells during the recovery phase of disease (21 days post-
injection), concomitant with a decrease in the proportion of
IL-17+ CD4+ cells in T-HIF-1a/ animals (Figures 6D and 6E).
This altered balance between Treg cells and TH17 cells exactly
parallels our in vitro culture studies and suggests that HIF-1a
indeed plays a role in modulating the TH17/Treg balance. Taken
together, these results support the notion that HIF-1 plays
a role in setting the TH17/Treg balance in a TH17-dependent
disease model and that the mechanisms defined in the in vitro
differentiation assays are also operative in vivo (Figure 7).
DISCUSSION
Here, we identify HIF-1 as a major player in the development of
TH17 cells and further demonstrate its role in modulating the
TH17:Treg balance. Specifically, HIF-1 promotes TH17 develop-
ment through: (1) direct transcriptional activation of RORgt, the
major TH17 transcription factor, and (2) direct collaboration
with RORgt to activate TH17 signature genes, such as IL-17A,
through mechanisms involving p300 recruitment and histone
acetylation. Other transcription factors have been identified to
contribute to the induction of IL-17A in TH17- polarized cells:
Runx1 (Zhang et al., 2008), BATF (Schraml et al., 2009), Stat3,
c-Maf (Bauquet et al., 2009), AHR (Veldhoen et al., 2008), and
RORa (Yang et al., 2008b). Interestingly, like most of these
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Figure 6. Mice Lacking HIF-1a in CD4+ T Cells Are Deficient in IL-17 Production, Have Increased Numbers of Foxp3 Treg, and Are More
Resistant to EAE
(A) EAE was induced in HIF-1a+/+ and T-HIF-1a/mice by injection of MOG35–55 in CFA and Pertussis Toxin. Disease severity was monitored and scored daily.
T-HIF-1a/ mice failed to develop the severe disease seen in HIF-1a+/+ mice. Mean scores for HIF-1a+/+ and T-HIF-1a/ mice over time are represented (±
SEM; *p < 0.05). Shown is a representative of four experiments (n = 7–10 per group).
(B and C) During peak disease (day12), draining lymph node, splenic, and CNS-infiltrating T cells were recovered and stained for IL-17 and IFNg. The mean
percentage of CNS CD4+ cells during peak disease (days 12–14) that were positive for IL-17 was determined (C).
(D and E) Similarly, during the recovery phase (day 21), tissue-infiltrating cells were isolated, and the percentage of CD4+ that were Foxp3+ was found (D and E).
(C) and (E) present the mean (± SEM; *p < 0.05) of at least three trials, and dot plots are representative analyses.factors, HIF-1a not only regulates RORgt expression at the
mRNA level, but also cooperates with RORgt protein to regulate
IL-17A-related genes during TH17 development. HIF-1 may
promote the TH17 response in additional ways. Indeed, studies
by Miossec and colleagues indicate that the hypoxia-induced
pathway is itself activated by IL-17A and IL-17F (Hot and
Miossec, 2011), suggesting that IL-17 signaling can sustain the
HIF-1 pool and thereby perpetuate an existing TH17response.
Coordinate with these transcriptional mechanisms for the
promotion of TH17 development, HIF-1 inhibits differentiation
toward the Treg lineage through a distinct, nontranscriptional
mechanism.We show that HIF-1 targets Foxp3 for ubiquitinationand proteasomal degradation, using the same ubiquitin ligase
system that is responsible for degradation of HIF-1a itself
(Figure 7).
Our findings help to clarify the molecular events involved in
lineage differentiation from the precursors of TH17 and Treg cells
into the distinct T cell subsets. In addition, because HIF-1
responds to metabolic cues, our findings link metabolism to
T cell differentiation and provide a basis for understanding how
the metabolic environment of a T cell can modulate its fate deci-
sions. Our studies on HIF-1 presented here and those of
Delgoffe et al. (Delgoffe et al., 2009, 2011; Delgoffe and Powell,
2009) and Shi et al. (Shi et al., 2011) on the mTOR pathwayCell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc. 781
Figure 7. A Model for the Multifactorial Role of HIF-1 in Modulating the TH17/Treg Balance
Stat3 activation by factors such as IL-6 transcriptionally activates HIF-1. HIF-1 levels are further regulated by oxygen tension and other metabolites, representing
a key molecular link between metabolic cues and T cell lineage commitment. HIF-1 directly activates Rorc gene transcription and, furthermore, recruits p300 to
RORgt transcription complexes on the promoters of TH17 genes (i.e., Il17). These activities promote TH17 differentiation. Concomitantly, HIF-1 induces Foxp3
protein degradation via targeting for ubiquitination and proteasomal degradation.further link metabolic sensing and cytokine signaling in T cell fate
determination.
HIF-1 is a major sensor of oxygen tension, and indeed, we
found that TH17 differentiation is enhanced under hypoxia in
a HIF-1a-dependent manner. Interestingly, a number of studies
have demonstrated that inflammatory environments are rela-
tively hypoxic. It is therefore likely that HIF-1a activity represents
a major mechanism by which the hypoxic conditions associated
with inflammation can promote TH17 differentiation. It is quite
clear, however, that HIF-1a protein is readily detectable in
TH17 cells under normoxia, and the experiments utilizing
HIF-1a/ T cells confirm that, under such conditions, TH17
differentiation is significantly impaired without HIF-1a. Even
though HIF-1 was originally discovered as a hypoxia sensor,
it is now well appreciated that HIF-1a levels can be significantly
affected by many other important metabolites such as reactive
oxygen species and succinate (Pouysse´gur and Mechta-
Grigoriou, 2006). This regulation appears to be at the level of
PHD enzyme activity, which in normoxia hydroxylates specific
prolines on HIF-1a, targeting it for VHL-dependent ubiquitination
and proteosomal degradation.
Our findings regarding the role of HIF-1 in targeting Foxp3 for
degradation help to explain the unresolved question of how dual
TH17/Treg precursors that express both RORgt and Foxp3 even-
tually eliminate Foxp3 when they commit to TH17 differentiation
in a STAT3-dependent fashion. Rudensky and colleagues
have recently proposed that conserved noncoding sequence 2782 Cell 146, 772–784, September 2, 2011 ª2011 Elsevier Inc.(CNS2) in the Foxp3 gene represents a site for positive transcrip-
tional autoregulation of Foxp3, providing a mechanism for the
protein to maintain its own expression levels (Zheng et al.,
2010). Thus, degradation of Foxp3 in TH17/Treg progenitors
mediated by HIF-1 would be expected to eventually diminish
Foxp3 gene transcriptional activity, thereby antagonizing stable
Foxp3 autoregulation and consequent Treg lineage commitment.
Sitkovsky and colleagues have suggested that HIF-1 activity
in T cells is a general negative regulator of T cell activation (Luka-
shev et al., 2006). These experiments did not evaluate specific
T cell differentiation decisions, however. We found that neither
IFN-g nor IL-4 production was significantly affected by the
absence of HIF-1 in T cells cultured under Th1 or Th2 conditions,
respectively. Because TH17 cytokines can inhibit Th1/IFN-g
development in some circumstances (Luger et al., 2008), it is
possible that the enhanced IFN-g production seen in HIF-1a/
T cells under the nonskewing in vitro conditions used by
Lukashev et al. is, in fact, a reflection of diminished TH17
development.
Our in vivo findings demonstrate that mice with HIF-1a/
T cells are resistant to induction of EAE, a TH17-dependent
disease whose remission is dependent upon Treg cells (Schraml
et al., 2009). These experiments validate the role of HIF-1a iden-
tified by our in vitro studies and further suggest the possibility of
metabolically modulating autoimmune diseases. Indeed, there is
great interest in developing HIF-1a inhibitors based on its role in
cancer. It would be worthwhile to determine whether any of
these inhibitors can alter the TH17:Treg balance in vivo and
ameliorate TH17-dependent autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice
All animal experiments were performed in specific pathogen-free facilities in the
Johns Hopkins Animal Resource Center following national, state, and insti-
tutional guidelines. Animal protocols were approved by the Johns Hopkins
Animal Care and Use Committee. Foxp3-GFP mice (Fontenot et al., 2005) were
kindly provided by A. Rudensky. C57BL/6 HIF-1afl/fl mice were produced in
Dr. Semenza’s lab. Rorc/mice were purchased from the Jackson Laboratory.
T Cell Differentiation
Naive T cells were purified using a FACS Aria sorter prior to stimulation with
anti-CD3 /CD28 antibodies in a 24-well plate (1 and 4 mg/well, respectively;
Biolegend) for 3–7 days. TH17-skewing conditions consisted of IMDM media
supplemented with 5% FBS, 20 ng/ml IL-6, 2.5 ng/ml TGFb (Peprotech), and
10 ug/ml neutralizing antibodies against IFNg, IL-4, and IL-12 (Biolegend).
For hypoxia experiments, cells were cultured in a GasPak Plus anaerobic
chamber (1% O2) for 20 hr cycles interrupted by normoxic rest.
Quantitative RT-PCR
RNAwas isolated by a miniRNA extraction kit (QIAGEN). The cDNA archival kit
(Applied Biosystem) was used as per the manufacturer’s instruction. Triplicate
reactions were run using an ABI Prism 7500. mRNA levels were determined by
comparative CT method and normalized to b-actin or 18 s rRNA expression.
EAE Induction
Six- to eight-week-old, sex-matched WT and T-HIF-1a/ littermates
were injected s.c in the rear flank with 100 mg MOG35–55 peptide (2HN-
MEVGWYRSPFSRVVHLYRNGK-COOH) in complete Freund’s adjuvant
(Sigma), and 250 ng pertussis toxin (List Biological) was injected i.p. Mice
were monitored daily, and disease severity was scored.
Immunoprecipitation and Western Blotting
Immunoprecipitation and western blotting were performed as elsewhere (Pan
et al., 2005). Immunoprecipitations were done using a Pierce Crosslink IP kit
and clean-Blot IP detection system (Thermo Scientific).
Reporter Gene Assays
The luciferase reporter gene assay reagents were obtained fromPromega, and
the assay was performed per manufacturer’s instructions.
Chromatin Immunoprecipitation Assays
ChIP analysis was carried out according to the manufacturer’s Millipore,
Massachusetts, USA). Briefly, cells (1-/Millipore, Massachusetts, USA). The
amount of immunoprecipitated DNA was quantified by real-time PCR with
the ABI PRISM 7500 Sequence Detection System (Applied Biosystems) using
SYBR Green. All primers used for ChIP assays are listed in Table S1.
GST Pull-Down
Cell lysate or purified protein was incubated with 3 mg of affinity-purified GST
protein (with a GSTrap column, Amersham) in the presence of 0.2% BSA in
BC100 Buffer on a rotator overnight at 4C. Proteins were pulled down using
GST beads, followed by washing, glutathione elution, and resolution by
SDS-PAGE.
Statistical Analysis
An unpaired Student’s t test was used to determine significance (*p < 0.05).
SUPPLEMENTAL INFORMATION
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